论文部分内容阅读
慢性乙型肝炎(CHB)抗病毒治疗已获得巨大进步,同时也随之出现了许多亟待解决的临床热点问题。口服核苷(酸)类似物治疗可使临床大多数患者达到持续抑制乙型肝炎病毒脱氧核糖核酸(HBV DNA)复制这一现实目标,但要实现阻止、延缓肝脏疾病进展,防止、减少终末期肝病发生的长远目标,
Chronic hepatitis B (CHB) antiviral therapy has made great progress, but also there have been many urgent clinical hot issues to be solved. Oral administration of nucleoside (acid) analogues can achieve the realistic goal of sustained inhibition of hepatitis B virus DNA (HBV DNA) replication in most clinical patients, but it is necessary to achieve the goal of preventing and slowing the progress of liver diseases, preventing and reducing the end-stage The long-term goal of liver disease,